Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quercetin-3-docosahexaenoic acid-7-isopropyl is a synthetic polyunsaturated alkylated lipophenol designed as a hybrid molecule for the treatment of neurodegenerative diseases, specifically Alzheimer's disease. It is a single pharmacological entity that covalently combines the antioxidant and anti-carbonyl stress properties of the flavonoid quercetin with the anti-inflammatory benefits of the omega-3 fatty acid docosahexaenoic acid (DHA), further modified with an isopropyl group at the 7-position to enhance lipophilicity or stability. The molecule acts by scavenging toxic small aldehydes like acrolein and reducing oxidative stress, thereby protecting neuronal cells from carbonyl stress-induced apoptosis. Research indicates that this hybrid structure may offer superior neuroprotective effects compared to its individual components by addressing multiple detrimental mechanisms involved in neuronal cell loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quercetin-3-docosahexaenoic acid-7-isopropyl.